Arca
Skip to content
Tools
Tools

Polyneuropathy

Drug research and approvals for polyneuropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 165 studies of polyneuropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 25 drug trials for it since 2013, FDA has 9 approved and 5 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 165
  • Trials authorized in Canada: 25
  • FDA orphan approvals: 9
  • EU medicines: 6

Recruiting now

Newest posted first, of 165 recruiting on ClinicalTrials.gov ↗

How its trials ended

272 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 58 whose ending is known, 47% met their primary endpoint, 7% missed it and 47% stopped early.

  • Completed, result not reported10137%
  • Ongoing7427%
  • Status unknown3914%
  • Met its primary endpoint2710%
  • Stopped: other or unclear207%
  • Missed its primary endpoint41%
  • Stopped: enrollment or feasibility31%
  • Stopped: lack of efficacy21%
  • Stopped: sponsor or business decision21%

Trials authorized in Canada

The 10 newest of 25; search them all in Canada trials
May 29, 2026A phase 3, randomized, double-blind, multicenter, placebo-controlled study to evaluate efficacy and safety of inebilizumab in participants with chronic…Uplizna (inebilizumab)AmgenPending
Oct 28, 2025A phase 3, randomized, double-blinded, placebo-controlled study evaluating the efficacy and safety of empasiprubart iv in adults with chronic inflammatory…Empasiprubart (ARGX-117)argenx USPending
Aug 8, 2025Phase 3, randomized, double-blinded, double-dummy study evaluating the efficacy and safety of intravenous empasiprubart versus intravenous immunoglobulin in…Empasiprubart (ARGX-117) / Octagamargenx USOngoing
May 8, 2025A phase 2, open-label study to evaluate the safety, tolerability, and efficacy of intravenous NVG-2089 in participants with chronic inflammatory demyelinating…NVG-2089Nuvig Therapeutics, Inc.Closed
Mar 7, 2025A phase 2, open-label, proof-of-concept study to investigate the efficacy, safety and tolerability of TAK-411 in adult subjects with chronic inflammatory…TAK-411Takeda Pharmaceuticals USAOngoing
Feb 14, 2025Long-term extension study to evaluate the safety and efficacy of riliprubart (SAR445088) in participants with chronic inflammatory demyelinating polyneuropathy…Riliprubart (SAR445088)Sanofi-Aventis Canada IncPending
Aug 16, 2024A phase 2, randomized, double-blind, placebo-controlled, dose-finding study evaluating LY3848575 in chronic neuropathic pain associated with distal sensory…LY3848575Eli LillyOngoing
Jun 13, 2024A phase 3, randomized, double-blind, study evaluating efficacy and safety of riliprubart versus intravenous immunoglobulin (IVIG) in participants with chronic…Riliprubart (SAR445088)Sanofi-Aventis Canada IncOngoing
Apr 26, 2024A phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory…Riliprubart (SAR445088)Sanofi-Aventis Canada IncOngoing
Jun 9, 2023A phase 2b, multi-center, randomized, quadruple-blind, placebo-controlled study of batoclimab treatment in adult participants with active chronic inflammatory…Batoclimab (IMVT-1401)Immunovant Sciences GmbHClosed

FDA orphan designations

Approved first, then open designations, newest first
Apr 10, 2025Vyvgart HytruloTreatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)argenx BVApproved
Jun 21, 2024Vyvgart HytruloTreatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)argenx BVApproved
Jan 12, 2024HyQviaTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability…Takeda Development Center Americas, Inc.Approved
Dec 21, 2023WainuaTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adultsIonis Pharmaceuticals, Inc.Approved
Jun 13, 2022AmvuttraTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adultsAlnylam Pharmaceuticals, Inc.Approved
Oct 5, 2018Tegsedi™TEGSEDI® is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.Akcea Therapeutics, Inc.Approved
Aug 10, 2018OnpattroONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.Alnylam Pharmaceuticals, Inc.Approved
Mar 15, 2018HizentraIndicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to…CSL BehringApproved
Sep 12, 2008Gamunex-CTreatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for…Grifols Therapeutics, Inc.Approved
Mar 20, 2024PrednisoneTreatment of Chronic Inflammatory Demyelinating PolyneuropathySarcomed ABDesignated
Oct 14, 2021NipocalimabTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adult patientsJanssen Research & Development, LLCDesignated
Jul 21, 2021Anti-C1s Humanized IgG4 Monoclonal AntibodyTreatment of chronic inflammatory demyelinating polyneuropathySanofi GenzymeDesignated
Feb 14, 2018Recombinant humanized IgG4 monoclonal antibody against…Treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (CIDP)GeNeuro S.A.Designated
Jul 14, 2015Recombinant multimerized human IgG1 FcTreatment of chronic inflammatory demyelinating polyneuropathy (CIDP).Gliknik Inc.Designated

Medicines authorised in the EU

Newest first
Jul 17, 2025AttrogyDiflunisalPurpose Pharma International ABEMA ↗
Mar 6, 2025WainzuaEplontersenAstraZeneca ABEMA ↗
Sep 15, 2022AmvuttraVutrisiran · orphanAlnylam Netherlands B.V.EMA ↗
Aug 27, 2018OnpattroPatisiran · orphanAlnylam Netherlands B.V.EMA ↗
Jul 6, 2018TegsediInotersen · orphanAkcea Therapeutics Ireland LimitedEMA ↗
Nov 16, 2011VyndaqelTafamidis · orphanPfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.